For the next year, sell-side analysts are expecting EPS growth of 10.60% for MEDNAX, Inc. (NYSE:MD). Analysts are expecting an EPS change of 12.70% for the current year. Tracking company EPS may help to evaulate company stock value. Wall Street analysts polled by Thomson Reuters have a current recommendation of 2.20 on a consensus basis for the stock. On a number scale from 1 to 5, a 5 would represent a Strong Sell recommendation. A 1 rating would signify a Strong Buy. The same analysts see shares reaching $74.00 within the next year on a consensus basis.
At the time of writing, MEDNAX, Inc. (NYSE:MD) had hit $65.47. This represents a change from the opening price of -1.49%. The year-to-date performance of the stock is -7.68%. The monthly stock performance comes in at 1.71%. For the quarter, shares are performing at -11.76%. Weekly performance analysis shows the equity at -1.11%.
MEDNAX, Inc. shares are currently 6.63% away from the 52 week low. Alternately, the stock is -21.31% away from the 52 week high. The stock is 4.53% away from its 50 day low and -3.38% away from the 50 day high. Relative to the 20 day Simple Moving Average, shares are trading -0.45% off it. Shares are currently separated from the 50 day Simple Moving Average by -0.25%. Shares are currently separated from the 200 day Simple Moving Average by -3.46%. The company’s Relative Strength Index (RSI) currently stands at 48.22.
In terms of financials, we can look at several key indicators. The company has a Return on Assets of 7.20%, which is a key factor in determining the effectiveness of management’s use of assets to generate earnings. The company currently has a Return on Equity of 13.60% and a Return on Investment of 9.50%.
The information provided on this website is for individual use only and should be considered strictly informational in nature. The article is not advice, and should not be treated as such. We are in no way responsible for any investment loss or damages. All content in our articles is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our articles. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. We make no recommendation that the securities of the companies profiled or discussed in on our website should be purchased, sold or held by investors.